Enovis Corporation (NYSE: ENOV) announced it will host an investor conference call on August 6th, 2026 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results. The company will issue an earnings press release that morning, with the live webcast and presentation accessible from its website.

The article highlights four undervalued growth stocks positioned to benefit from long-term secular trends: Enovis (orthopedic implants driven by aging population), Insteel Industries (infrastructure and data center construction), Mueller Water Products (water infrastructure replacement), and Proto Labs (transitioning from prototyping to production manufacturing). All trade under $100 and are recommended for patient, long-term investors.

Front Street Capital Management purchased 384,124 additional shares of Enovis (ENOV) in Q1 2026 for approximately $9.08 million, increasing their stake to 2.25% of fund assets. The purchase signals institutional confidence in the medical device company despite ENOV shares being down 23.99% over the past year. Insider buying activity also suggests bullish sentiment, though the company reported a net loss of $1.14 billion in trailing twelve months.

Enovis Corporation (NYSE: ENOV) announced it will host an investor conference call on May 7th, 2026 at 8:30 a.m. ET to discuss first quarter 2026 financial results. The company reported continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically, with Reconstructive sales growing 10% year-over-year on a reported basis and 8% organically.

John Kleckner, Principal Accounting Officer of Enovis Corporation, purchased 2,468 shares on Nov. 25, 2025, signaling potential confidence in the company despite a challenging year with significant quarterly losses.

Enovis Corporation will participate in three investor conferences in August and September 2025, including Canaccord Genuity, Wells Fargo Healthcare, and Baird Global Healthcare Conferences.

Medical technology company Enovis reported Q2 2025 revenue of $564.5 million, up 7% year-over-year, beating analyst estimates. The company raised full-year guidance and saw strong performance in its Reconstructive segment, despite ongoing integration and regulatory challenges.

The orthopedic braces and supports market is projected to grow at a CAGR of 5.04% from 2024 to 2030, driven by the increasing burden of orthopedic conditions, sports-related injuries, and the development of smart and custom-made braces.

Enovis Corporation announced that CEO Matt Trerotola will retire, and the company is actively searching for his successor. Trerotola will remain as an executive advisor for a year to facilitate a smooth transition.

Enovis, a global medical technology company, announced that Davide Visentin will succeed Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025. Visentin is an experienced MedTech executive who previously held leadership roles at BD, Stryker, and Johnson & Johnson Depuy Synthes.

The manual cutting equipment market is predicted to reach USD 24.6 billion by 2032, driven by the growing construction industry and demand for efficient cutting tools. The oxy-fuel segment and the construction sector are expected to witness significant growth during this period, particularly in Europe.

Enovis has introduced the AltiVate Reverse Glenoid System, a new solution for reverse shoulder arthroplasty. The system offers modular and augmented baseplates, providing surgeons with more options to improve implant longevity and optimize patient outcomes.